Event Markers Swimmer Plot Example Data
Source:R/data_swimmer_unified_docs.R
swimmer_unified_events.RdA longitudinal dataset designed to demonstrate event marker functionality. Shows multiple timeline segments per patient with different clinical events, treatments, and adverse event management.
Usage
data(swimmer_unified_events)Format
A data frame with 20 rows and 6 variables:
- PatientID
Character. Patient identifiers (multiple rows per patient)
- StartTime
Numeric. Segment start time in months
- EndTime
Numeric. Segment end time in months
- Response
Character. Response during this segment (CR, PR, SD, PD)
- EventType
Character. Type of clinical event (Treatment Start, Dose Escalation, etc.)
- EventTime
Numeric. Time when the event occurred
See also
Other swimmer plot datasets:
swimmer_unified_basic,
swimmer_unified_comprehensive,
swimmer_unified_datetime,
swimmer_unified_oncology
Examples
data(swimmer_unified_events)
# Event markers swimmer plot
swimmerplot(
data = swimmer_unified_events,
patientID = "PatientID",
startTime = "StartTime",
endTime = "EndTime",
responseVar = "Response",
showEventMarkers = TRUE,
eventVar = "EventType",
eventTimeVar = "EventTime",
markerSize = 6,
plotTheme = "ggswim"
)
#>
#> SWIMMER PLOT
#> NOTE: Ongoing-treatment arrows not drawn
#> Ongoing-status arrows require a censoring/event status variable. Without one, whether a patient was still on treatment at data cutoff cannot be determined from the timeline alone, so no arrows are drawn. Supply a censoring variable (0/FALSE/no/censored/alive for ongoing, 1/TRUE/yes/event/dead for completed) to show them.
#> <div style='color: #8a6d00; background-color: #fff8e1; padding: 15px;
#> border: 1px solid #ffc107; border-radius: 5px; margin: 10px;'>
#>
#> Analysis Information
#>
#> Found 15 duplicate patient IDs. Multiple episodes per patient detected
#> - this is normal for longitudinal data.
#>
#> Timeline Summary Statistics
#> ───────────────────────────────────────────
#> Metric Value
#> ───────────────────────────────────────────
#> Number of Patients 10.000000
#> Total Observations 25.000000
#> Median Duration (observed) 9.500000
#> Mean Duration 9.700000
#> Total Person-Time 97.000000
#> Mean Follow-up 9.700000
#> CR Rate (%) 30.000000
#> PD Rate (%) 20.000000
#> PR Rate (%) 30.000000
#> SD Rate (%) 20.000000
#> ───────────────────────────────────────────
#>
#>
#> <div style='background-color: #e8f5e8; padding: 15px; border-radius:
#> 5px; margin: 10px 0;'>
#>
#> Clinical Interpretation
#>
#> <div style='margin: 10px 0;'><h5 style='color: #2e7d32;'>Timeline
#> Analysis:
#>
#> Study included 10 patients with 25 timeline observations. Median
#> observed duration was 9.5 months (range: 5.0 to 15.0 months).
#>
#> <div style='margin: 10px 0;'><h5 style='color: #2e7d32;'>Person-Time
#> Analysis:
#>
#> Total person-time: 97.0 months. Average follow-up per patient: 9.7
#> months.
#>
#> <div style='margin: 10px 0;'><h5 style='color: #2e7d32;'>Response
#> Pattern Analysis:
#>
#> Most common response was CR (30.0% of patients). Response distribution
#> shows clinical patterns suitable for efficacy analysis.
#>
#> Person-Time Analysis
#> ─────────────────────────────────────────────────────────────────────────────
#> Response Type Patients Total Time Mean Time Follow-up Density
#> ─────────────────────────────────────────────────────────────────────────────
#> CR 3 35.00000 11.670000 8.571000
#> PD 2 16.00000 8.000000 12.500000
#> PR 3 24.00000 8.000000 12.500000
#> SD 2 22.00000 11.000000 9.091000
#> ─────────────────────────────────────────────────────────────────────────────
#>
#>
#> Milestone Event Summary
#> ────────────────────────────────────────────────────
#> Milestone Events Median Time Time Range
#> ────────────────────────────────────────────────────
#> ────────────────────────────────────────────────────
#>
#>
#> Event Marker Summary
#> ─────────────────────────────────────────────────────────────
#> Event Type Count Percentage Median Time
#> ─────────────────────────────────────────────────────────────
#> Dose Modification 6 24.00000 5.000000
#> Hospitalization 3 12.00000 5.000000
#> Response Assessment 5 20.00000 4.000000
#> Scan 7 28.00000 4.000000
#> Toxicity 4 16.00000 5.000000
#> ─────────────────────────────────────────────────────────────
#>
#>
#> Advanced Clinical Metrics
#> ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
#> Metric Value 95% CI Unit Clinical Interpretation
#> ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
#> Median Follow-up Time (observed durations; no censoring information) 9.500000 months Central tendency of patient follow-up duration
#> Interquartile Range (observed durations) 4.500000 months Middle 50% of follow-up duration range
#> Total Study Person-Time 97.000000 months cumulative Total observation time across all patients
#> Follow-up Density 10.309000 per 100 months Number of patients per 100 units of observation time (descriptive metric)
#> Objective Response Rate (ORR) 60.000000 26.2 - 87.8 percent Proportion with complete or partial response
#> Disease Control Rate (DCR) 80.000000 44.4 - 97.5 percent Proportion with response or stable disease
#> ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
#>
